Concentra Group Holdings Parent, Inc. CON
CON among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
CON and 9 peers, year by year
The 9 Health care companies closest to CON in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Gross margin | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|
| CON Concentra Group Holdings Parent, Inc. | FY2025 | $2.2B | +13.9% | - | 15.4% | 7.7% | 9.1% | 42.3% | 4.00 |
| ENOV Enovis CORP | FY2025 | $2.2B | +6.7% | 59.8% | −50.0% | −52.7% | 0.9% | −79.5% | 0.87 |
| RDNT RadNet, Inc. | FY2025 | $2.0B | +11.5% | - | 3.0% | −0.9% | - | −1.7% | 1.00 |
| TFX Teleflex Inc | FY2025 | $2.0B | +17.2% | 56.2% | 5.9% | −45.4% | 0.1% | −29.0% | 0.85 |
| PRVA Privia Health Group, Inc. | FY2025 | $2.1B | +22.3% | - | 1.6% | 1.1% | - | 3.1% | - |
| ICUI ICU Medical Inc | FY2025 | $2.2B | −6.3% | 36.8% | 1.9% | 0.0% | 4.1% | 0.0% | 0.60 |
| EXEL Exelixis, Inc. | FY2025 | $2.3B | +7.0% | - | 37.6% | 33.7% | 37.7% | 36.2% | - |
| MRNA Moderna | FY2025 | $1.9B | −39.9% | - | −158.1% | −145.2% | −106.2% | −32.6% | 0.07 |
| QDEL QuidelOrtho Corp | FY2025 | $2.7B | −1.9% | - | −33.7% | −41.5% | −3.0% | −58.9% | 1.40 |
| RPRX Royalty Pharma plc | FY2025 | $2.4B | +5.1% | - | 65.6% | 32.4% | - | 7.9% | 0.92 |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2022 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2022 to FY2025
Revenue as reported in the 10-K.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| CON Dec | $1.7B | $1.8B | $1.9B | $2.2B |
| ENOV Dec | $1.6B | $1.7B | $2.1B | $2.2B |
| RDNT Dec | $1.4B | $1.6B | $1.8B | $2.0B |
| TFX Dec | $2.8B | $1.7B | $1.7B | $2.0B |
| PRVA Dec | $1.4B | $1.7B | $1.7B | $2.1B |
| ICUI Dec | $2.3B | $2.3B | $2.4B | $2.2B |
| EXEL Jan | $1.6B | $1.8B | $2.2B | $2.3B |
| MRNA Dec | $19.3B | $6.8B | $3.2B | $1.9B |
| QDEL Dec | $3.3B | $3.0B | $2.8B | $2.7B |
| RPRX Dec | $2.2B | $2.4B | $2.3B | $2.4B |
| Peer median | $2.2B | $1.8B | $2.2B | $2.2B |
Sales growth, FY2022 to FY2025
Revenue against the fiscal year before.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| CON Dec | - | +6.6% | +3.4% | +13.9% |
| ENOV Dec | +9.6% | +9.2% | +23.5% | +6.7% |
| RDNT Dec | +8.7% | +13.0% | +13.2% | +11.5% |
| TFX Dec | −0.7% | +6.6% | −0.8% | +17.2% |
| PRVA Dec | +40.4% | +22.2% | +4.7% | +22.3% |
| ICUI Dec | +73.2% | −0.9% | +5.4% | −6.3% |
| EXEL Jan | +12.3% | +13.6% | +18.5% | +7.0% |
| MRNA Dec | +4.3% | −64.4% | −52.7% | −39.9% |
| QDEL Dec | +92.3% | −8.2% | −7.2% | −1.9% |
| RPRX Dec | −2.3% | +5.2% | −3.9% | +5.1% |
| Peer median | +9.6% | +6.6% | +4.7% | +6.7% |
Gross margin, FY2022 to FY2025
Gross profit / revenue.
Operating margin, FY2022 to FY2025
Operating income / revenue.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| CON Dec | 15.0% | 15.6% | 16.0% | 15.4% |
| ENOV Dec | −4.6% | −3.8% | −36.8% | −50.0% |
| RDNT Dec | 3.2% | 6.1% | 5.7% | 3.0% |
| TFX Dec | 17.9% | 15.1% | 6.1% | 5.9% |
| PRVA Dec | −1.4% | 1.2% | 1.0% | 1.6% |
| ICUI Dec | −1.9% | 1.0% | 1.8% | 1.9% |
| EXEL Jan | 12.5% | 9.3% | 27.9% | 37.6% |
| MRNA Dec | 48.9% | −61.9% | −121.9% | −158.1% |
| QDEL Dec | 25.8% | 4.6% | −70.5% | −33.7% |
| RPRX Dec | 13.7% | 63.4% | 57.1% | 65.6% |
| Peer median | 12.5% | 4.6% | 1.8% | 1.9% |
Net margin, FY2022 to FY2025
Net income / revenue.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| CON Dec | 9.7% | 9.8% | 8.8% | 7.7% |
| ENOV Dec | −0.9% | −1.9% | −39.2% | −52.7% |
| RDNT Dec | 0.7% | 0.2% | 0.2% | −0.9% |
| TFX Dec | 13.0% | 20.8% | 4.1% | −45.4% |
| PRVA Dec | −0.6% | 1.4% | 0.8% | 1.1% |
| ICUI Dec | −3.3% | −1.3% | −4.9% | 0.0% |
| EXEL Jan | 11.3% | 11.4% | 24.0% | 33.7% |
| MRNA Dec | 43.4% | −68.8% | −110.0% | −145.2% |
| QDEL Dec | 16.8% | −0.3% | −73.7% | −41.5% |
| RPRX Dec | 1.9% | 48.2% | 37.9% | 32.4% |
| Peer median | 1.9% | 0.2% | 0.2% | −0.9% |
Free cash flow, FY2022 to FY2025
Cash from operations minus capital spending.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| CON Dec | $228.4M | $169.4M | $210.3M | $197.1M |
| ENOV Dec | −$161.3M | $12.8M | −$67.2M | $19.9M |
| RDNT Dec | - | - | - | - |
| TFX Dec | $263.6M | $159.7M | $211.4M | $1.4M |
| PRVA Dec | $47.1M | $80.7M | - | - |
| ICUI Dec | −$152.4M | $82.3M | $124.7M | $91.8M |
| EXEL Jan | $334.9M | $292.9M | $671.5M | $875.8M |
| MRNA Dec | $4.6B | −$3.8B | −$4.1B | −$2.1B |
| QDEL Dec | $744.4M | $70.9M | −$112.1M | −$83.0M |
| RPRX Dec | - | - | - | - |
| Peer median | $263.6M | $80.7M | $28.7M | $10.7M |
FCF margin, FY2022 to FY2025
Free cash flow / revenue.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| CON Dec | 13.2% | 9.2% | 11.1% | 9.1% |
| ENOV Dec | −10.3% | 0.7% | −3.2% | 0.9% |
| RDNT Dec | - | - | - | - |
| TFX Dec | 9.4% | 9.3% | 12.4% | 0.1% |
| PRVA Dec | 3.5% | 4.9% | - | - |
| ICUI Dec | −6.7% | 3.6% | 5.2% | 4.1% |
| EXEL Jan | 20.8% | 16.0% | 31.0% | 37.7% |
| MRNA Dec | 23.8% | −55.9% | −125.3% | −106.2% |
| QDEL Dec | 22.8% | 2.4% | −4.0% | −3.0% |
| RPRX Dec | - | - | - | - |
| Peer median | 9.4% | 3.6% | 1.0% | 0.5% |
Return on equity, FY2022 to FY2025
Net income / shareholders' equity at the year end.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| CON Dec | 17.0% | 15.5% | 60.4% | 42.3% |
| ENOV Dec | −0.4% | −1.0% | −32.2% | −79.5% |
| RDNT Dec | 3.2% | 0.5% | 0.3% | −1.7% |
| TFX Dec | 9.0% | 8.0% | 1.6% | −29.0% |
| PRVA Dec | −1.7% | 4.1% | 2.3% | 3.1% |
| ICUI Dec | −3.6% | −1.4% | −6.0% | 0.0% |
| EXEL Jan | 7.3% | 9.2% | 23.2% | 36.2% |
| MRNA Dec | 43.7% | −34.0% | −32.7% | −32.6% |
| QDEL Dec | 11.1% | −0.2% | −68.8% | −58.9% |
| RPRX Dec | 0.4% | 11.3% | 8.3% | 7.9% |
| Peer median | 3.2% | 0.5% | 0.3% | −1.7% |
Debt / equity, FY2022 to FY2025
Total debt / shareholders' equity at the year end.
EPS (diluted), FY2022 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| CON Dec | $1.60 | $1.73 | $1.46 | $1.30 |
| ENOV Dec | −$0.25 | −$0.61 | −$14.93 | −$20.75 |
| RDNT Dec | $0.17 | $0.05 | $0.04 | −$0.25 |
| TFX Dec | $7.68 | $7.53 | $1.48 | −$20.25 |
| PRVA Dec | −$0.08 | $0.19 | $0.11 | $0.18 |
| ICUI Dec | −$3.11 | −$1.23 | −$4.83 | $0.03 |
| EXEL Jan | $0.56 | $0.65 | $1.76 | $2.78 |
| MRNA Dec | $20.12 | −$12.33 | −$9.28 | −$7.26 |
| QDEL Dec | $9.56 | −$0.15 | −$30.54 | −$16.69 |
| RPRX Dec | $0.10 | $2.53 | $1.91 | $1.78 |
| Peer median | $0.17 | $0.05 | $0.04 | −$0.25 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out CON and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: CON's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CON/export.csv") into a cell.